Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Algernon Pharmaceuticalsinc (AGN.CN)

Algernon Pharmaceuticalsinc (AGN.CN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Algernon Pharmaceuticalsinc 700 West Pender Street Suite 915 Vancouver BC V6C 1G8 CAN

P: 604-646-1553

Description:

Algernon Pharmaceuticals Inc is a clinical stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough, and COVID-19. The company operates in two reportable segments being the development of repurposed therapeutic drugs in Canada and the facilitation of the company's lead drug candidates into off-label phase II clinical trials (humans) in Australia. Its business model is capital efficient and strives to deliver maximum shareholder value. Algernon's unique approach to drug discovery is based on the concept of drug repurposing.

Key Statistics

Overview:

Market Capitalization, $K 14,236
Shares Outstanding, K 167,487
Annual Sales, $ 0 K
Annual Net Income, $ -8,538 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -1,674 K
60-Month Beta 0.02
% of Institutional Shareholders 1.12%

Growth:

1-Year Return -71.43%
3-Year Return -55.00%
5-Year Return -83.02%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.08
EPS Growth vs. Prev Year 26.95%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-2 on 10/17/18

AGN.CN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -90.85%
Return-on-Assets % -80.37%
Profit Margin % 0.00
Net Margin % N/A
Debt/Equity N/A
Price/Sales N/A
Price/Book 1.46
Book Value/Share 0.06
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar